176 related articles for article (PubMed ID: 9673264)
21. A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines.
Barkoff AM; Guiso N; Guillot S; Xing D; Markey K; Berbers G; Mertsola J; He Q
J Immunol Methods; 2014 Jun; 408():142-8. PubMed ID: 24925807
[TBL] [Abstract][Full Text] [Related]
22. Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activity.
Aase A; Herstad TK; Merino S; Bolstad M; Sandbu S; Bakke H; Aaberge IS
Clin Vaccine Immunol; 2011 Aug; 18(8):1269-74. PubMed ID: 21677109
[TBL] [Abstract][Full Text] [Related]
23. [Serum immunoglobulin IgG subclass distribution of antibody responses to pertussis toxin and filamentous hemagglutinin of Bordetella pertussis in patients with whooping cough].
Rastawicki W; Smietańska K; Rokosz-Chudziak N; Jagielski M
Med Dosw Mikrobiol; 2013; 65(4):269-74. PubMed ID: 24730215
[TBL] [Abstract][Full Text] [Related]
24. Stability of antibodies to Bordetella antigens in German adults.
Saemann-Ischenko G; Tillmanns B; Kösters K; Riffelmann M; Wirsing von König CH
Eur J Clin Microbiol Infect Dis; 2001 Dec; 20(12):850-3. PubMed ID: 11837635
[TBL] [Abstract][Full Text] [Related]
25. Determination of pertactin IgG antibodies for the diagnosis of pertussis.
Trollfors B; Lagergård T; Gunnarsson E; Taranger J
Clin Microbiol Infect; 2003 Jul; 9(7):585-9. PubMed ID: 12925096
[TBL] [Abstract][Full Text] [Related]
26. Granulocyte-macrophage colony-stimulating factor DNA prime-protein boost strategy to enhance efficacy of a recombinant pertussis DNA vaccine.
Li QT; Zhu YZ; Chu JY; Dong K; He P; Feng CY; Hu BY; Zhang SM; Guo XK
Acta Pharmacol Sin; 2006 Nov; 27(11):1487-94. PubMed ID: 17049126
[TBL] [Abstract][Full Text] [Related]
27. Specific immune response in adult medical personnel immunized with acellular pertussis vaccine with special emphasis on T helper cell response.
Lin TY; Chiang BL
Vaccine; 1997 Dec; 15(17-18):1917-21. PubMed ID: 9413102
[TBL] [Abstract][Full Text] [Related]
28. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine.
Thomas MG; Ashworth LA; Miller E; Lambert HP
J Infect Dis; 1989 Nov; 160(5):838-45. PubMed ID: 2572651
[TBL] [Abstract][Full Text] [Related]
29. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
[TBL] [Abstract][Full Text] [Related]
30. Protective role of immunoglobulin G antibodies to filamentous hemagglutinin and pertactin of Bordetella pertussis in Bordetella parapertussis infection.
He Q; Edelman K; Arvilommi H; Mertsola J
Eur J Clin Microbiol Infect Dis; 1996 Oct; 15(10):793-8. PubMed ID: 8950556
[TBL] [Abstract][Full Text] [Related]
31. Construction and characterization of single-chain variable fragment antibodies directed against the Bordetella pertussis surface adhesins filamentous hemagglutinin and pertactin.
Hussein AH; Davis EM; Halperin SA; Lee SF
Infect Immun; 2007 Nov; 75(11):5476-82. PubMed ID: 17724067
[TBL] [Abstract][Full Text] [Related]
32. Immune responses to Bordetella pertussis infection and vaccination.
Tomoda T; Ogura H; Kurashige T
J Infect Dis; 1991 Mar; 163(3):559-63. PubMed ID: 1995729
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity of a new enhanced tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine against Bordetella pertussis in a murine model.
Kang KR; Huh DH; Kim JA; Kang JH
BMC Immunol; 2021 Oct; 22(1):68. PubMed ID: 34641798
[TBL] [Abstract][Full Text] [Related]
34. Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens.
Macdonald-Fyall J; Xing D; Corbel M; Baillie S; Parton R; Coote J
Vaccine; 2004 Oct; 22(31-32):4270-81. PubMed ID: 15474718
[TBL] [Abstract][Full Text] [Related]
35. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines.
Ausiello CM; Lande R; Urbani F; la Sala A; Stefanelli P; Salmaso S; Mastrantonio P; Cassone A
Infect Immun; 1999 Aug; 67(8):4064-71. PubMed ID: 10417175
[TBL] [Abstract][Full Text] [Related]
36. Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory.
Stenger RM; Smits M; Kuipers B; van Gaans-van den Brink J; Poelen M; Boog CJ; van Els CA
Vaccine; 2010 Sep; 28(40):6637-46. PubMed ID: 20637762
[TBL] [Abstract][Full Text] [Related]
37. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
[TBL] [Abstract][Full Text] [Related]
38. Mucosal and systemic immune responses elicited by recombinant Lactococcus lactis expressing a fusion protein composed of pertussis toxin and filamentous hemagglutinin from Bordetella pertussis.
Torkashvand A; Bahrami F; Adib M; Ajdary S
Microb Pathog; 2018 Jul; 120():155-160. PubMed ID: 29738814
[TBL] [Abstract][Full Text] [Related]
39. Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines.
Boros CA; Hanlon M; Gold MS; Roberton DM
Vaccine; 2001 May; 19(25-26):3537-42. PubMed ID: 11348721
[TBL] [Abstract][Full Text] [Related]
40. Antibody and cell-mediated immune responses to booster immunization with a new acellular pertussis vaccine in school children.
Tran Minh NN; Edelman K; He Q; Viljanen MK; Arvilommi H; Mertsola J
Vaccine; 1998 Oct; 16(17):1604-10. PubMed ID: 9713935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
